

Faster, cheaper and under control: de-risking CMC development with transposon-derived manufacturing cell lines

Sowmya Rajendran¹, Sowmya Balasubramanian¹, Lynn Webster¹, Maggie Lee¹, Divya Vavilala¹, Nicolay Kulikov¹, Jessica Choi¹, Calvin Tang¹, Molly Hunter¹, Rebecca Wang¹, Harpreet Kaur¹, Surya Karunakaran¹, Varsha Sitaraman¹, Jeremy Minshull¹, and Ferenc Boldog¹

¹ATUM

July 30, 2020

Abstract

The development of highly productive, genetically stable manufacturing cell lines is on the critical path to IND filing for protein based biologic drugs. Here we describe Leap-In Transposase® platform, a novel transposon-based mammalian (e.g. CHO) cell line development system that produces high titer stable pools with productivity and product quality attributes that are highly comparable to clones that are subsequently derived therefrom. The productivity distributions of clones are strongly biased towards high producers and both genetic and expression stability is consistently high. By avoiding the poor integration rates, concatemer formation, detrimental transgene recombination, low average expression level, unpredictable product quality and inconsistent genetic stability characteristic of non-homologous recombination methods, Leap-In provides several opportunities to de-risk programs early and reduce timelines and resources.

Hosted file

CLD Transposon_20200727.pdf available at <https://authorea.com/users/347429/articles/473119-faster-cheaper-and-under-control-de-risking-cmc-development-with-transposon-derived-manufacturing-cell-lines>




FIGURE 1